NCT01596647 - Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Advanced Solid Tumors, Excluding Breast Cancer

Interventions

DRUG

caffeine

single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

DRUG

diclofenac

single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

DRUG

omeprazole

single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

DRUG

midazolam

single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam

DRUG

TKI258

dovitinib, 5 days on / 2 days off dose schedule

Trial Locations (5)

University of Minnesota, Minneapolis

University of Kansas Cancer Center Medical Center, Kansas City

Comprehensive Cancer Centers, Las Vegas

Henry Ford Hospital Henry Ford, Detroit

Cancer Institute of New Jersey Dept of Cancer Institute of NJ, New Brunswick